4-Amino-5-(5-methyl-1-phenyl-1
H-pyrazol-4-yl)-2,4-dihydro-3
H-1,2,4-triazole-3-thione (
1) upon treatment with 3,4-dimethoxybenzaldehyde in 10 mL of absolute ethanol in the presence of a catalytic amount of acetic acid produced the target compound 4-[(3,4-dimethoxybenzylidene)amino]-5-(5-methyl-1-phenyl-1
H-pyrazol-4-yl)-2,4-dihydro-3
H-1,2,4-triazole-3-thione (
2) in 80% yield.
[...] Read more.
4-Amino-5-(5-methyl-1-phenyl-1
H-pyrazol-4-yl)-2,4-dihydro-3
H-1,2,4-triazole-3-thione (
1) upon treatment with 3,4-dimethoxybenzaldehyde in 10 mL of absolute ethanol in the presence of a catalytic amount of acetic acid produced the target compound 4-[(3,4-dimethoxybenzylidene)amino]-5-(5-methyl-1-phenyl-1
H-pyrazol-4-yl)-2,4-dihydro-3
H-1,2,4-triazole-3-thione (
2) in 80% yield. The obtained solid product was recrystallized from ethanol. The compound was characterized by elemental analyses, mass spectrometry, FT-IR,
1H and
13C-NMR spectroscopy. To study the binding interactions of the compound with receptor, it was docked with the human prostaglandin reductase (PTGR2). The docking pose and noncovalent interactions gave insights into its plausible inhibitory action.
Full article